A prediction system of oxidation reaction as a solid-state stress condition: Applied to a pyrrole-containing pharmaceutical compound

Journal of Pharmaceutical and Biomedical Analysis

Volumn 50, Issue 3, 2009, Pages 328-335

  Kawaguchi Murakami, Yoko ^a,b   Fukutsu, Naoto ^a   Kajiro, Toshi ^a   Araki, Tetsuya ^a   Murakami, Tomonori ^a   Kawasaki, Takao ^a,c,d   Kishi, Naoyuki ^a   Konno, Michiko ^b  

^a DAIICHI SANKYO CO   (Japan)

^b OCHANOMIZU UNIVERSITY   (Japan)

^c Institute of Applied Medicine Inc   (Japan)

^d SHOWA UNIVERSITY   (Japan)

Author keywords

Degradation product; Oxidation; Prediction system; Pyrrole; Solid state; Stress condition

Indexed keywords

4 METHYL 2 (3,4 DIMETHYLPHENYL) 1 (4 SULFAMOYLPHENYL)PYRROLE; HYDROGEN PEROXIDE; PYRROLE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; DRUG DEGRADATION; DRUG STABILITY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; OXIDATION; PREDICTION; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SOLID STATE;

CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, LIQUID; DRUG STABILITY; HYDROGEN PEROXIDE; MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY; OXIDATION-REDUCTION; PYRROLES; SULFONAMIDES;

EID: 67650220911     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpba.2009.04.032     Document Type: Article

References (35)

1. International Conference on Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH Harmonised Tripartite Guideline Q1A(R2): Stability Testing of New Drug Substances and Products, Step 4, 6 February 2003, Available at: http://www.ich.org/.
2. International Conference on Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH Harmonised Tripartite Guideline Q1E: Evaluation for stability data, Step 4, 6 February 2003, Available at: http://www.ich.org/.
3. International Conference on Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH Harmonised Tripartite Guideline Q3A(R2): Impurities in New Drug Substances, Step 4, 25 October 2006, Available at: http://www.ich.org/.
4. International Conference on Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH Harmonised Tripartite Guideline Q3B(R2): Impurities in New Drug Products, Step 4, 2 June 2006, Available at: http://www.ich.org/.
5. Alsante K.M., Ando A., Brown R., Ensing J., Hatajik T.D., Kong W., and Tsuda Y. Adv. Drug Deliv. Rev. 59 (2007) 29-37
6. Olsen B.A., Perry F.M., Snorek S.V., and Lewellen P.L. Pharm. Dev. Technol. 2 (1997) 303-312
7. Jin P., Madieh S., and Augsburger L. AAPS PharmSciTech 8 (2007) 200-205
8. Sims J.L., Carreira J.A., Carrier D.J., Crabtree S.R., Easton L., Hancock S.A., and Simcox C.E. Pharm. Dev. Technol. 8 (2003) 119-126
9. Jelinska A., Dudzinska I., Zajac M., and Oszczpowicz I. J. Pharm. Biomed. Anal. 41 (2006) 1075-1081
10. Guillory J.K., and Poust R.I. In: Banker G.S., and Rhodes C.T. (Eds). Modern Pharmaceutics. fourth ed. (2002), Informa Healthcare, USA 146-173
11. Hovorka S., and Schoneich C. J. Pharm. Sci. 90 (2001) 253-269
12. Waterman K.C., Adami R.C., Alsante K.M., Hong J., Landis M.S., Lombardo F., and Roberts C.J. Pharm. Dev. Technol. 7 (2002) 1-32
13. Nelson E.D., Harmon P.A., Szymanik R.C., Teresk M.G., Li L., Seburg R.A., and Reed R.A. J. Pharm. Sci. 95 (2006) 1527-1539
14. Harmon P.A., Kosuda K., Nelson E., Mowery M., and Reed R.A. J. Pharm. Sci. 95 (2006) 2014-2028
15. Seburg R.A., Ballard J.M., Hwang T.L., and Sullivan C.M. J. Pharm. Biomed. Anal. 42 (2006) 411-422
16. Alsante K.M., Martin L., and Baertschi S.W. Pharm. Technol. (2003) 60-72
17. Laus G. J. Chem. Soc. Perkin Trans. 2 (2001) 864-868
18. Nelson E.D., Thompson G.M., Yao Y., Flanagan H.M., and Harmon P.A. J. Pharm. Sci. 98 (2009) 959-969
19. Templeton A.C., and Reed R.A. In: Swarbrick J. (Ed). Encyclopedia of Pharmaceutical Technology. third ed. (2006), Informa Healthcare, USA 1967-1976
20. Ogilby P.R., and Foote C.S. J. Am. Chem. Soc. 105 (1983) 3423-3430
21. Hammond J., and Jones I. In: Smith R.J., and Webb M.L. (Eds). Analysis of Drug Impurities (2007), Blackwell Publishing, Oxford 156-214
22. Tollsten L. In: Gorog S. (Ed). Identification and Determination of Impurities in Drugs (2000), Elsevier, Amsterdam 266-298
23. Wu Y. Biomed. Chromatogr. 14 (2000) 384-396
24. Ermer J., and Vogel M. Biomed. Chromatogr. 14 (2000) 373-383
25. Wilson I.D., Griffiths L., Lindon J.C., and Nicholson J.K. In: Gorog S. (Ed). Identification and Determination of Impurities in Drugs (2000), Elsevier, Amsterdam 299-322
26. Peng S.X. Biomed. Chromatogr. 14 (2000) 430-441
27. Lindon J.C., Nicholson J.K., and Wilson I.D. In: Albert K. (Ed). On-line LC-NMR and Related Techniques (2002), Wiley, Chichester 45-88
28. Baranczewski P., Kautiainen A., Kautiainen A., Sandin P., and Edlund P.O. Pharmacol. Rep. 58 (2006) 341-352
29. Sun M., Dai W., and Liu D.Q. J. Mass Spectrom. 43 (2008) 383-393
30. Gawinecki R., Kolehmainen E., and Kauppinen R. J. Chem. Soc. Perkin Trans. 2 (1998) 25-30
31. Gossauer A., and Nesvadba P. In: Jones R.A. (Ed). Pyrroles: Part One: The Synthesis and the Physical and Chemical Aspects of the Pyrrole Ring (Chemistry of Heterocyclic Compounds) (1990), John Wiley & Sons, New York 499-536
32. Bocchi L.C.V., Gardini G.P., and Mondelli R. Tetrahedron 26 (1970) 4073-4082
33. Dalvie D.K., Kalgutkar A.S., Khojasteh-Bakht S.C., Obach R.S., and O'Donnell J.P. Chem. Res. Toxicol. 15 (2002) 269-299
34. Beaver B.D., Cooney J.V., John J., and Watkins M. J. Heterocycl. Chem. 23 (1986) 1095-1097
35. Li H.-Y., Drummondb S., DeLuccab I., and Boswell G.A. Tetrahedron 52 (1996) 11153-11162